#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	15240	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2059	735.5	1	SNP	n	C1184T	0	.	.	1184	1184	C	1432	1432	C	913	C,A	833,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	15240	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2059	735.5	0	HET	.	.	.	C1089T	.	1089	1089	C	1337	1337	C	823	C,T	595,173	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28464	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3478	815.8	0	.	n	.	0	T695C	SNP	695	695	T	1014	1014	C	878	C,T,A	801,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28464	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3478	815.8	0	.	n	.	0	G1337A	SNP	1337	1337	G	1656	1656	A	989	A,G	901,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28464	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3478	815.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2290	2290	C	934	C,T	834,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28464	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3478	815.8	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2916	2916	T	873	T,C	816,4	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28464	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3478	815.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2364	2364	A	900	A,G	834,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	1948	folP	852	852	100.0	folP.l15.c4.ctg.1	1456	133.2	1	SNP	p	R228S	1	.	.	682	684	AGC	986	988	AGC	201;200;201	A,G;G;C	182,1;183;183	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5160	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3365	153.0	1	SNP	p	S91F	0	.	.	271	273	TCC	527	529	TCC	165;163;161	T;C;C	154;154;148	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5160	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3365	153.0	1	SNP	p	D95G	0	.	.	283	285	GAC	539	541	GAC	168;171;170	G;A;C	153;155;155	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5160	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3365	153.0	1	SNP	p	D95N	0	.	.	283	285	GAC	539	541	GAC	168;171;170	G;A;C	153;155;155	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1584	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1406	112.3	0	.	p	.	0	A39T	NONSYN	115	117	GCC	438	440	ACC	188;188;187	A;C;C	164;169;169	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1584	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1406	112.3	0	.	p	.	0	R44H	NONSYN	130	132	CGC	453	455	CAC	184;183;184	C;A,G;C	168;164,1;165	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1584	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1406	112.3	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	636	638	CAC	207;204;205	C;A;C	193;190;193	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1584	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1406	112.3	1	SNP	p	G45D	0	.	.	133	135	GGC	456	458	GGC	188;188;188	G;G;C	170;171;172	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	890	mtrR_promoter	250	250	100.0	mtrR_promoter.l6.c17.ctg.1	942	93.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5390	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2858	187.9	1	SNP	p	D86N	0	.	.	256	258	GAC	465	467	GAC	236;233;237	G,A;A;C	216,1;213;221	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5390	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2858	187.9	1	SNP	p	S87I	0	.	.	259	261	AGT	468	470	AGT	240;239;240	A;G;T	221;222;222	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5390	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2858	187.9	1	SNP	p	S87R	0	.	.	259	261	AGT	468	470	AGT	240;239;240	A;G;T	221;222;222	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5390	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2858	187.9	1	SNP	p	S87W	0	.	.	259	261	AGT	468	470	AGT	240;239;240	A;G;T	221;222;222	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5390	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2858	187.9	1	SNP	p	S88P	0	.	.	262	264	TCC	471	473	TCC	242;242;243	T;C,A;C	223;216,1;221	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4352	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2578	168.1	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1526	1528	GGC	222;216;214	G;G;C	199;194;192	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	3900	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2383	162.9	1	SNP	p	A311V	0	.	.	931	933	GCA	1258	1260	GCA	204;205;205	G;C;A	187;190;189	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3900	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2383	162.9	1	SNP	p	I312M	0	.	.	934	936	ATC	1261	1263	ATC	206;206;207	A;T;C	189;192;195	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3900	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2383	162.9	1	SNP	p	V316P	0	.	.	946	948	GTG	1273	1275	GTG	213;209;209	G;T;G	198;192;193	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3900	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2383	162.9	1	SNP	p	V316T	0	.	.	946	948	GTG	1273	1275	GTG	213;209;209	G;T;G	198;192;193	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3900	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2383	162.9	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1777	1779	ACC	228;231;231	A,T,C;C;C	201,1,1;213;214	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3900	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2383	162.9	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1831	1833	GCG	227;223;220	G;C,G;G	200;173,2;186	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3900	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2383	162.9	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1831	1833	GCG	227;223;220	G;C,G;G	200;173,2;186	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3900	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2383	162.9	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1954	1956	GGC	186;185;183	G;G;C	168;167;165	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3900	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2383	162.9	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1963	1965	GGC	173;171;167	G;G,A;C	158;154,1;154	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3900	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2383	162.9	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1981	1983	CCG	151;152;154	C,G;C;G,C	113,7;121;119,1	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	5742	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3157	181.5	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1635	1637	CTG	197;201;204	C;T,C;G	181;186,1;189	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2290	porA	1146	1146	99.83	porA.l15.c30.ctg.1	1939	118.0	0	.	p	.	0	M83fs	FSHIFT	247	247	A	580	580	C	146	C	133	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2874	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1552	184.3	0	.	p	.	0	E48G	NONSYN	142	144	GAA	496	498	GGA	225;225;227	G;G;A,T	208;209;209,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2874	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1552	184.3	0	.	p	.	0	F135L	NONSYN	403	405	TTT	757	759	CTT	198;197;199	C;T,A;T	180;180,1;184	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2874	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1552	184.3	0	.	p	.	0	R143G	NONSYN	427	429	AGA	781	783	GGA	195;195;195	G,C;G,A;A	171,1;171,1;169	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2874	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1552	184.3	0	.	p	.	0	D171G	NONSYN	511	513	GAT	865	867	GGT	199;203;201	G;G,A;T,C	187;185,2;179,2	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2874	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1552	184.3	0	.	p	.	0	S175P	NONSYN	523	525	TCA	877	879	CCA	214;219;222	C,T;C;A	193,2;201;204	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2874	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1552	184.3	0	.	p	.	0	G189S	NONSYN	565	567	GGC	919	921	AGC	232;231;229	A;G,A;C	204;201,1;203	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2874	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1552	184.3	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	985	985	T	202	T	191	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2874	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1552	184.3	1	SNP	p	G120K	0	.	.	358	360	GGT	712	714	GGT	203;203;207	G,T;G;T	191,1;191;190	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2874	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1552	184.3	1	SNP	p	A121N	0	.	.	361	363	GCC	715	717	GCC	205;202;203	G;C;C	188;188;191	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2874	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1552	184.3	1	SNP	p	A121D	0	.	.	361	363	GCC	715	717	GCC	205;202;203	G;C;C	188;188;191	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	11002	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4696	233.6	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1913	1915	AAT	240;239;240	A;A;T	221;221;221	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1242	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	957	128.7	1	SNP	p	V57M	1	.	.	169	171	ATG	489	491	ATG	279;282;280	A;T;G	262;263;263	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
